Non-Hodgkin lymphoma

Abstract

Non-Hodgkin lymphoma (NHL) is the seventh most common cancer in the UK and represents a heterogenous group of malignancies. This article gives a brief overview of the current classification of B and T cell NHL, the molecular and cytogenetic abnormalities associated with their pathogenesis, and principles for managing them. Although advances in immuno-chemotherapy and supportive care have resulted in better patient outcomes, many challenges remain, especially for individuals with relapsed and refractory disease.